Evidence map›Paper›PMID 32175023›Full record

ArticleAsian journal of pharmaceutical sciences2020

Simvastatin nanoliposome induces myocardial and hepatic toxicities due to its absorption enhancement in mice.

Nuerbiye Tuerdi, Gulinigaer Anwaier, Xing Zhang, Shu Liu, Wanli Shen, Wen Liu, Qiang Shen, Rong Qi

Open access · diamondAbstract read
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nuerbiye TuerdiSchool of Basic Medical Science, Shihezi University, Shihezi 832008, China.
Gulinigaer AnwaierSchool of Basic Medical Science, Shihezi University, Shihezi 832008, China.
Xing ZhangMinistry of Education, School of Pharmacy, Shihezi University, Shihezi 832008, China.
Shu LiuMinistry of Education, School of Pharmacy, Shihezi University, Shihezi 832008, China.
Wanli ShenMinistry of Education, School of Pharmacy, Shihezi University, Shihezi 832008, China.
Wen LiuThe First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi 832008, China.
Qiang ShenPeking University Health Science Center, Institute of Cardiovascular Sciences, Peking University, Beijing 100191, China.
Rong QiSchool of Basic Medical Science, Shihezi University, Shihezi 832008, China.
Peking University · CNShihezi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoliposome is a useful dosage form to increase solubility and absorption of simvastatin (SMV), and consequently improves its therapeutic effects. However,

Indexed as

HepatotoxicityMuscular toxicityMyocardiotoxicityNanoliposomeSimvastatin

Identifiers

PMID32175023
PMCPMC7066038
OpenAlexW2945455222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.